Search

Displaying results 3361 - 3370 of 4600 in total
  1. Drug

    ISO-1 F-18

    go.drugbank.com/drugs/DB14900
    Investigational

    ISO-1 F-18 is under investigation in clinical trial NCT00968656 (Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1).

  2. Drug

    Digoxigenin

    go.drugbank.com/drugs/DB03671
    Experimental

    Can be obtained by hydrolysis of digoxin or from Digitalis orientalis L. and Digitalis lanata Ehrh.

  3. Drug

    SR-123781A

    go.drugbank.com/drugs/DB05361
    Investigational

    It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).

  4. Drug

    IP501

    go.drugbank.com/drugs/DB06450
    Experimental

    The compound was developed by Indevus Pharmaceuticals.

  5. Drug

    BMS-986251

    go.drugbank.com/drugs/DB19007
    Investigational

    BMS-986251 is under investigation in clinical trial NCT03329885 (A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

  6. Drug

    Nezastomig

    go.drugbank.com/drugs/DB19061
    Investigational

    Nezastomig is under investigation in clinical trial NCT06085664 (A Pilot Presurgical Trial of REGN5678 (Anti-psma X CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

  7. Drug

    BI-K0376

    go.drugbank.com/drugs/DB05858
    Experimental

    It is under investigation by Pfizer and has gone through phase I of the clinical trails.

  8. Drug

    ST-36

    go.drugbank.com/drugs/DB17275
    Experimental

    In 2017, it received orphan drug designation by the FDA for the treatment of glioma.[L47341]

  9. Drug

    Inetetamab

    go.drugbank.com/drugs/DB17457
    Investigational

    It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.

  10. Drug

    HMI-203

    go.drugbank.com/drugs/DB18520
    Investigational

    HMI-203 is an investigational gene therapy developed by Homology Medicines, Inc.